Blog
RSS FeedPosted by Michael Wonder on 21 Jun 2024
Outcomes from the May 2024 PBAC intracycle meeting
21 June 2024 - Recommendations made by the PBAC in May 2024 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 29 Apr 2024
Life prolonging breast cancer drug recommended for PBS subsidy, but it is not time to celebrate
26 April 2024 - Breast Cancer Network Australia (BCNA) today welcomed a decision by the PBAC to recommend the life ...
Posted by Michael Wonder on 26 Apr 2024
Recommendations made by the PBAC (March 2024)
26 April 2024 - Recommendations made by the PBAC in March 2024 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 22 Mar 2024
Outcome statement - February 2024 DUSC meeting
22 March 2024 - The Outcome Statement from the February 2024 DUSC meeting is now available. ...
Posted by Michael Wonder on 01 Mar 2024
More rare conditions considered for newborn bloodspot screening and new treatment option for spinal muscular atrophy
29 February 2024 - On Rare Disease Day, the Albanese Government has announced two more rare genetic conditions have been ...
Posted by Michael Wonder on 26 Jan 2024
Outcomes from the December 2023 PBAC intracycle meeting
25 January 2024 - The outcomes from the December 2023 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 17 Dec 2023
Recommendations made by the PBAC (November 2023)
18 December 2023 - Recommendations made by the PBAC in November 2023 relating to the listing of medicines on the ...
Posted by Michael Wonder on 13 Oct 2023
Outcomes of the September 2023 PBAC intracycle meeting
13 October 2023 - The outcomes from the September 2023 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 29 Aug 2023
Australia knocks back application for diabetes drug that could overshadow Ozempic
29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants ...
Posted by Michael Wonder on 21 Aug 2023
Recommendations made by the PBAC (July 2023)
18 August 2023 - Recommendations made by the PBAC in July 2023 relating to the listing of medicines on the ...
Posted by Michael Wonder on 18 Aug 2023
Estimating overall survival in people receiving PBS listed cancer medicines in Australian clinical practice
18 August 2023 - In September 2021, the Department of Health and Aged Care contracted the Medicines Intelligence Centre for ...
Posted by Michael Wonder on 18 Jul 2023
Outcome statement - June 2023 DUSC meeting
18 July 2023 - The outcome statement from the June 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 23 Jun 2023
Changes to PBS eligibility criteria for Paxlovid
23 June 2023 - In an out of session consideration, the PBAC has recommended changes to the circumstances under which nirmatrelvir ...
Posted by Michael Wonder on 16 Jun 2023
Outcomes of the May 2023 PBAC intracycle meeting
16 June 2023 - The outcomes from the May 2023 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 24 May 2023
Revolutionising MS treatment: new form of Tysabri recommended for PBS listing
24 May 2023 - The PBAC has recommended the listing of natalizumab (Tysabri) pre-filled syringe for subcutaneous injection on the PBS. ...